Dignify Therapeutics

Develops on-demand drugs that let people with spinal cord injury and other neurological conditions empty the bladder or bowel when they choose. Lead candidate DTI-117, a short-acting peptide, received FDA clearance of its IND in October 2026 for a Phase 1 study funded by the NIH.